Clinical Trials Browser

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

Clinical Trials

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

CARMENA

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

OCCLURANDOM

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

ASSET

ImmunoSarc

Phase II Study of Alternating Sunitinib and Temsirolimus

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

FIRSTMAPPP

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

SATURNE

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

SURE

BIONIKK

ICK

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)

SUP-R

INMUNOSUN

IIT Sutent

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Bevacizumab in Multiple Phase I Combinations

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

RESUNET

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years

Erlotinib and Sunitinib in NSCLC

SUAVE

FARETES

Sutent

SOGANG

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

MetAction

FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

BERAT

KOSMIC

Sunitinib in Never-Smokers With Lung Adenocarcinoma

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer